# A Retrospective Study to Evaluate the Early Real-world Evidence of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD) in India

> **NCT05834075** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 63 (actual)

## Conditions studied

- Neurovascular Age-related Macular Degeneration

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05834075
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-05
- **Primary completion:** 2022-04-22
- **Final completion:** 2022-04-22
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2023-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05834075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05834075, "A Retrospective Study to Evaluate the Early Real-world Evidence of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD) in India". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05834075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*